SCHEMBL23640288

SCHEMBL23640288

O=C(O)Cc1noc2ccc3cc(O)ccc3c12

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
ESR1 P03372 10/20 0.42
ESR2 Q92731 10/20 0.42
LCK P06239 1/20 0.41
FYN P06241 1/20 0.41
AKR1B1 P15121 1/20 0.41
GRB2 P62993 1/20 0.41
THRA P10827 1/20 0.39
THRB P10828 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 2/20 0.38
HNF4A P41235 1/20 0.37
HSP90AA1 P07900 1/20 0.36
CA12 O43570 1/20 0.36
MCL1 Q07820 1/20 0.36
CA9 Q16790 1/20 0.36
ACHE P22303 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23640325 0.85 MAPT (0.49) MAPTAKR1B1SMN1; SMN2KDM4E
SCHEMBL23640304 0.85 MAPT (0.49) MAPTAKR1B1THRBSMN1; SMN2KDM4E
SCHEMBL23639978 0.83 ALDH1A1 (0.43) MAPTESR1ESR2AKR1B1SMN1; SMN2
SCHEMBL9036818 0.80 MAPT (0.70) MAPTESR1ESR2LCKFYN
SCHEMBL24939758 0.80 MAPT (0.57) MAPTESR1ESR2LCKFYN
SCHEMBL24302589 0.76 MAPT (0.50) MAPTESR1ESR2THRBSMN1; SMN2
SCHEMBL24950261 0.74 KDM4E (0.68) MAPTLCKFYNAKR1B1GRB2
SCHEMBL23640218 0.73 MAPT (0.47) MAPTAKR1B1SMN1; SMN2KDM4E
SCHEMBL24753979 0.73 SMN1; SMN2 (0.47) MAPTAKR1B1SMN1; SMN2KDM4E
SCHEMBL11211516 0.71 MAPT (0.50) MAPTAKR1B1THRBSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-04-21 US disclosed
EP-3848367-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2021-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CRBN, CSNK2A1, CSNK2A2 MAPT 539/4885ESR1 3760/4885ESR2 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.